Chickenpox party or varicella vaccine?

Advances in Experimental Medicine and Biology

Volumn 568, Issue , 2005, Pages 11-24

  Hambleton, Sophie ^a   Arvin, Ann M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; LIVE VACCINE;

CHICKENPOX; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG MONITORING; DRUG SAFETY; HEALTH PROGRAM; HERPES ZOSTER; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOGENICITY; INCIDENCE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; VACCINATION; VARICELLA ZOSTER VIRUS; ECONOMICS; UNITED STATES; VIRUS LATENCY;

HERPES ZOSTER; HUMAN HERPESVIRUS 3;

CHICKENPOX; CHICKENPOX VACCINE; HERPES ZOSTER; HUMANS; UNITED STATES; VACCINATION; VACCINES, ATTENUATED; VIRUS LATENCY;

EID: 25144439895     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/0-387-25342-4_2     Document Type: Review

References (71)

1. Arvin, A.M. (1996). Immune responses to varicella-zoster virus. Infect. Dis. Clin. North Am. 10, 529-570.
2. Arvin, A.M. (2001). Varicella vaccine: Genesis, efficacy, and attenuation. Virology 284, 153-158.
3. Arvin, A.M. and Gershon, A.A. (1996). Live attenuated varicella vaccine. Annu. Rev. Microbiol. 50, 59-100.
4. Arvin, A.M., Koropchak, C.M., and Wittek, A.E. (1983). Immunologic evidence of reinfection with varicella-zoster virus. J. Infect. Dis. 148, 200-205.
5. Berger, R., Florent, G., and Just, M. (1981). Decrease of the lympho-proliferative response to varicella-zoster virus antigen in the aged. Infect. Immun. 32, 24-27.
6. Brisson, M., Edmunds, W.J., Law, B., Gay, N.J., Walld, R., Brownell, M. et al. (2001). Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol. Infect. 127, 305-314.
7. Brisson, M., Gay, N.J., Edmunds, W.J., and Andrews, N.J. (2002). Exposure to varicella boosts immunity to herpes-zoster: Implications for mass vaccination against chickenpox. Vaccine 20, 2500-2507.
8. Centers for Disease Control. (1996). Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mort. Week. Rep. 45, 1-36.
9. Centers for Disease Control. (1999). Prevention of varicella. Updated recommendations of the Advisory Committee on Immunization Practices. Morb. Mort. Week. Rep. 48(RR06), 1-6.
10. Centers for Disease Control. (2000). Varicella outbreaks among Mexican adults - Alabama, 2000. Morb. Mort. Week. Rep. 49, 735-736.
11. Centers for Disease Control. (2003). Decline in annual incidence of varicella - selected states, 1990-2001. Morb. Mort. Week. Rep. 52, 884-885.
12. Centers for Disease Control. (2004). National, State, and Urban Area Vaccination Coverage Among Children Aged 19-35 months - United States, 2003. Morb. Mort. Week. Rep. 53, 658-661.
13. Clements, D.A., Zaref, J.I., Bland, C.L., Walter, E.B., and Coplan, P. (2001). Partial uptake of varicella vaccine and the epidemiological effect on varicella disease in 11 day-care centers in North Carolina. Arch. Pediatr. Adolesc. Med. 155, 455-461.
14. Committee on Infectious Diseases. (1995). Recommendations for the use of live attenuated varicella vaccine. American Academy of Pediatrics. Pediatrics 95, 791-796.
15. Donahue, J.G., Choo, P.W., Manson, J.E., and Platt, R. (1995). The incidence of herpes zoster. Arch. Intern. Med. 155, 1605-1609.
16. Edmunds, W.J., Brisson, M., and Rose, J.D. (2001). The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 19, 3076-3090.
17. Galil, K., Brown, C., Lin, F., and Seward, J. (2002a). Hospitalizations for varicella in the United States, 1988-1999. Pediatr. Infect. Dis. J. 121, 931-935.
18. Galil, K., Fair, E., Mountcastle, N., Britz, P., and Seward, J. (2002b). Younger age at vaccination may increase risk of varicella vaccine failure. J. Infect. Dis. 186, 102-105.
19. Galil, K., Lee, B., Strine, T., Carraher, C., Baughman, A.L., Eaton, M. et al. (2002c). Outbreak of varicella at a day-care center despite vaccination. N. Engl. J. Med. 347, 1909-1915.
20. Gershon, A.A. (2001). Zoster in immunosuppressed patients. In C.P.N. Watson and A. Gershon (eds.), Herpes Zoster and Postherpetic Neuralgia. Elsevier, Amsterdam, pp. 107-117.
21. Gershon, A.A. (2003). Varicella vaccine: Rare serious problems-But the benefits still outweigh the risks. J. Infect. Dis. 188, 945-947.
22. Gershon, A.A., Steinberg, S., LaRussa, P., Hammerschlag, M., Ferrara, A., and NIAID Collaborative Varicella Vaccine Study Group. (1988). Immunization of healthy adults with live attenuated varicella vaccine. J. Infect. Dis. 158, 132-137.
23. Gershon, A.A., Takahashi, M., and Seward, J. (2004). Varicella vaccine. In S. Plotkin and W. Orenstein (eds.), Vaccines, 4th Edn. WB Saunders, Philadelphia, PA, pp. 783-823.
24. Ghaffar, F., Carrick, K., Rogers, B.B., Margraf, L.R., Krisher, K., and Ramilo, O. (2000). Disseminated infection with varicella-zoster virus vaccine strain presenting as hepatitis in a child with adenosine deaminase deficiency. Pediatr. Infect. Dis. J. 19, 764-766.
25. Gilden, D.H., Kleinschmidt-DeMasters, B.K., LaGuardia, J.J., Mahalingham, R., and Cohrs, R.J. (2000). Neurologic complications of the reactivation of varicella-zoster virus. N. Engl. J. Med. 342, 635-645.
26. Gnann, J.W., Jr. and Whitley, R.J. (2002). Clinical practice. Herpes zoster. N. Engl. J. Med. 347, 340-346.
27. Guess, H.A., Broughton, D.D., Melton, L.J., and Kurland, L. (1986). Population-based studies of varicella complications. Pediatrics 78(S), 723-727.
28. Halloran, E., Cochi, S., Lieu, T., Wharton, M., and Fehrs, L. (1994). Theoretical epidemiological and morbidity effects of routine immunization of preschool children with varicella vaccine in the United States. Am. J. Epidemiol. 140, 81-104.
29. Hardy, I.B., Gershon, A., Steinberg, S., and LaRussa, P. (1991). The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. N. Engl. J. Med. 325, 1545-1550.
30. Hata, A., Asanuma, H., Rinki, M., Sharp, M., Wong, R.M., Blume, K. et al. (2002). Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N. Engl. J. Med. 347, 26-34.
31. Hope-Simpson, R.E. (1952). Infectiousness of communicable diseases in the household (measles, mumps, and chickenpox). Lancet ii, 549-554.
32. Hope-Simpson, R.E. (1965). The nature of herpes zoster: A long term study and a new hypothesis, Proc. R. Soc. Med. 58, 9-20.
33. Izurieta, H., Strebel, P., and Blake, P. (1997). Post-licensure effectiveness of varicella vaccine during an outbreak in a child care center. J. Am. Med. Assoc. 278, 1495-1498.
34. Johnson, C., Stancin, T., Fattlar, D., Rome, L.P., and Kumar, M.L. (1997). A long-term prospective study of varicella vaccine in healthy children. Pediatrics 100, 761-766.
35. Kennedy, P.G. (2002). Varicella-zoster virus latency in human ganglia. Rev. Med. Virol. 12, 327-334.
36. Kramer, J.M., LaRussa, P., Tsai, W.C., Carney, P., Leber, S.M., Gahagan, S. et al. (2001). Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child. Pediatrics 108, E39.
37. Kumagai, T., Chiba, Y., Fujiyama, M., Hanzono, H., Nakamura, S., Chiba, S. et al. (1980). Humoral and cellular immune response to varicella-zoster virus in children inoculated with live attenuated varicella vaccine. Biken. J. 23, 135-141.
38. Kuter, B., Matthews, H., Shinefield, H., Black, S., Dennehy, P., Watson, B. et al. (2004). Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr. Infect. Dis. J. 23, 132-137.
39. Kuter, B.J., Weibel, R.E., Guess, H.A., Matthews, H., Morton, D.H., Neff, B.J. et al. (1991). Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 9, 643-647.
40. LaRussa, P. (2000). Clinical manifestations of varicella. In: Arvin A.M., and Gershon A. A. (eds), Varicella-zoster virus: virology and clinical management. Cambridge University Press, Cambridge, pp. 206-219.
41. Lee, B.R., Feaver, S.L., Miller, C.A., Hedberg, C.W., and Ehresmann, K.R. (2004). An elementary school outbreak of varicella attributed to vaccine failure: Policy implications. J. Infect. Dis. 190, 477-483.
42. Levin, M., Barber, D., Goldblatt, E., Jones, M., LaFleur, B., Chan, C. et al. (1998). Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J. Infect. Dis. 178, S109-S112.
43. Levin, M.J., Dahl, K.M., Weinberg, A., Giller, R., and Patel, A. (2003a). Development of resistance to acyclovir during chronic Oka strain varicella-zoster virus infection in an immunocompromised child. J. Infect. Dis. 188, 954-959.
44. Levin, M.J., Smith, J.G., Kaufhold, R.M., Barber, D., Hayward, A.R., Chan, C.Y. et al. (2003b). Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J. Infect. Dis. 188, 1336-1344.
45. Levy, O., Orange, J.S., Hibberd, P., Steinberg, S., LaRussa, P., Weinberg, A. et al. (2003). Disseminated varicella infection due to vaccine (Oka) strain varicella-zoster virus in a patient with a novel deficiency in natural killer cells. J. Infect. Dis. 188, 948-953.
46. Li, S., Chan, I., Matthews, H., Heyse, J., Chan, C., Kuter, B. et al. (2002). Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term break-through infection. Pediatr. Infect. Dis. J. 21, 337-342.
47. Lieu, T., Cochi, S., Black, S., Halloran, M.E., Shinefield, H.R., Holmes, S.J. et al. (1994). Cost-effectiveness of a routine varicella vaccination program for U.S. children. J. Am. Med. Assoc. 271, 375-381.
48. McCoy, L., Sorvillo, F., and Simon, P. (2004). Varicella-related mortality in California, 1988-2000. Pediatr. Infect. Dis. J. 23, 498-503.
49. Meyer, P., Seward, J.F., Jumaan, A.O., and Wharton, M. (2000). Varicella mortality: Trends before vaccine licensure in the United States, 1970-1994. J. Infect. Dis. 182, 383-390.
50. Moffat, J.F., Zerboni, L., Kinchington, P., Grose, C., Kaneshima, H., and Arvin, A. (1998). Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J. Virol. 72, 965-974.
51. Oxman, M.N. (2000). Clinical manifestations of herpes zoster. In A. Arvin and A. Gershon (eds.), Varicella-Zoster Virus: Virology and Clinical Management. Cambridge University Press, Cambridge, pp. 246-275.
52. Peterson, C., Mascola, L., Chao, S.M., Lieberman, J.M., Arcinue, E.L., Blumberg, D. et al. (1996). Children hospitalized for varicella: A prevaccine review. J. Pediatr. 129, 529-536.
53. Rentier, B. and Gershon, A.A. (2004). Consensus: Varicella vaccination of healthy children - A challenge for Europe. Pediatr. Infect. Dis. J. 23, 379-389.
54. Ryan, M.A., Smith, T.C., Honner, W.K., and Gray, G.C. (2003). Varicella susceptibility and vaccine use among young adults enlisting in the United States Navy. J. Med. Virol. 70 (Suppl 1), S15-S19.
55. Seward, J.F., Galil, K., and Wharton, M. (2000). Epidemiology of varicella. In A. Arvin and A. Gershon (eds.), Varicella-Zoster Virus: Virology and Clinical Management. Cambridge University Press, Cambridge, pp. 187-205.
56. Seward, J.F., Watson, B.M., Peterson, C.L., Mascola, L., Pelosi, J.W., Zhang, J.X. et al. (2002). Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. J. Am. Med. Assoc. 287, 606-611.
57. Seward, J.F., Zhang, J.X., Maupin, T.J., Mascola, L., and Jumaan, A.O. (2004). Contagiousness of varicella in vaccinated cases: A household contact study. J. Am. Med. Assoc. 292, 704-708.
58. Sharrar, R.G., LaRussa, P., Galea, S., Steinberg, S., Sweet, A., Keatley, M. et al. (2001). The postmarketing safety profile of varicella vaccine. Vaccine 19, 916-923.
59. Smith, J.G., Levin, M., Vessey, R., Chan, I.S., Hay ward, A.R., Liu, X. et al. (2003). Measurement of cell-mediated immunity with a varicella-zoster virus-specific interferon-gamma ELISPOT assay: responses in an elderly population receiving a booster immunization. J. Med. Virol. 70 (Suppl 1), S38-S41.
60. Thomas, S., Wheeler, J., and Hall, A.J. (2002). Contacts with varicella or with children and protection against herpes zoster in adults: A case-control study. Lancet 360, 678-682.
61. Tsolia, M., Gershon, A., Steinberg, S., and Gelb, L. (1990). Live attenuated varicella vaccine: Evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. J. Pediatr. 116, 184-189.
62. Varis, T. and Vesikari, T. (1996). Efficacy of high titer live attenuated varicella vaccine in healthy young children. J. Infect. Dis. 174, S330-S334.
63. Vazquez, M., LaRussa, P.S., Gershon, A.A., Niccolai, L.M., Muehlenbein, C.E., Steinberg, S.P. et al. (2004). Effectiveness over time of varicella vaccine. J. Am. Med. Assoc. 291, 851-855.
64. Verstraeten, T., Jumaan, A.O., Mullooly, J.P., Seward, J.F., Izurieta, H.S., DeStefano, F. et al. (2003). A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination. Pediatrics 112, e98-e103.
65. Watson, B., Rothstein, E., Bernstein, H., Arbeter, A., Arvin, A., Chartrand, S. et al. (1995). Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J. Infect. Dis. 172, 217-219.
66. Weibel, R., Neff, B.J., Kuter, B.J., Guess, H.A., Rothenberger, C.A., Fitzgerald, A.J. et al. (1984). Live attenuated varicella virus vaccine: Efficacy trial in healthy children. N. Engl. J. Med. 310, 1409-1415.
67. Wharton, M. (1996). The epidemiology of varicella-zoster virus infections. Infect. Dis. Clin. North Am. 10, 571-581.
68. White, C.J. (1996). Clinical trials of varicella vaccine in healthy children. Infect. Dis. Clin. N. Amer. 10, 595-608.
69. White, C.J., Kuter, B.J., Hildebrand, C.S., Isganitis, K.L., Matthews, H., Miller, W.J. et al. (1991). Varicella vaccine (VARIVAX) in healthy children and adolescents: Results from clinical trials, 1987 to 1989. Pediatrics 87, 604-610.
70. Wise, R.P., Salive, M.E., Braun, M.M., Mootrey, G.T., Seward, J.F., Rider, L.G. et al. (2000). Postlicensure safety surveillance for varicella vaccine. J. Am. Med. Assoc. 284, 1271-1279.
71. Zerboni, L., Nader, S., Aoki, K., and Arvin, A.M. (1998). Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine. J. Infect. Dis. 177, 1701-1704.